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Abstract
Lung adenocarcinoma (AD) represents a predominant type of lung cancer demonstrating significant morphologic and
molecular heterogeneity. We sought to understand this heterogeneity by utilizing gene expression analyses of 432 AD
samples and examining associations between 27 known cancer-related pathways and the AD subtype, clinical
characteristics and patient survival. Unsupervised clustering of AD and gene expression enrichment analysis reveals that
cell proliferation is the most important pathway separating tumors into subgroups. Further, AD with increased cell
proliferation demonstrate significantly poorer outcome and an increased solid AD subtype component. Additionally, we
find that tumors with any solid component have decreased survival as compared to tumors without a solid component.
These results lead to the potential to use a relatively simple pathological examination of a tumor in order to determine its
aggressiveness and the patient’s prognosis. Additional results suggest the ability to use a similar approach to determine a
patient’s sensitivity to targeted treatment. We then demonstrated the consistency of these findings using two independent
AD cohorts from Asia (N=87) and Europe (N=89) using the identical analytic procedures.
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Introduction
Lung cancer is the second most common cancer in the United
States and the most common cause of cancer-related death [1].
The overall five-year survival rate is only 15% for lung cancer
patients and more than half of patients present with metastatic
disease at time of first diagnosis [2]. Patients with early stage
disease have a significantly better prognosis, therefore detecting
and diagnosing lung cancer early is extremely important [2].
Unfortunately, one third of patients with the earliest stage IA lung
cancer will succumb to their disease. Thus identifying high-risk
individuals and characterizing the cellular pathways underlying
aggressive lung cancer behavior may lead to better therapeutic
approaches to increase patient survival.
Non-small cell lung cancer (NSCLC) accounts for the majority
of lung cancer and adenocarcinomas (AD) and squamous cell
carcinomas (SCC) represent the most common types of NSCLC.
AD are increasing in incidence and we and others have recently
comprehensively examined large numbers of AD by gene
expression profiling [3], DNA copy number variation [4] and
the mutational status of key cancer-related genes [5]. Clinical
covariates such as age, gender and tumor stage offer prognostic
information and these factors were found to improve the
prognostic performance of gene-expression based predictors for
AD survival [3]. The molecular as well as the pathological
heterogeneity of lung adenocarcinomas (AD) has been described
[6], however the exact relationships between the specific AD
subtypes to each other, or to clinical and molecular variables has
not been adequately addressed. The foundation for classification of
AD is pathology with several subtypes being recognized [7]. These
include carcinoma in situ or CIS (formerly called bronchioalveolar
carcinoma or BAC), which retain the normal alveolar architecture
but with neoplastic cell replacement and a lepidic growth pattern.
The acinar AD subtype demonstrate the characteristic glandular
pattern, the papillary AD subtype shows finger-like tumor cell
projections with a sparce stromal core and the solid AD subtype
demonstrate a more compressed structure without features
associated with the other main subtypes.
The current system of AD classification does not adequately
capture the heterogeneity of these tumors and classification
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proaches tend to be treated as separate modalities. Investigating
the associations and interactions between them could yield
powerful new insights into more effective and clinically-relevant
ways to classify AD but has been hampered by previous gene
expression studies examining only relatively small numbers of
tumors. We have now combined our recent analysis of over 400
AD samples using gene expression profiling [3] with complete
clinical information and a newlyp e r f o r m e du n i f o r mp a t h o l o g -
ical review of these tumors. We hypothesized that the
heterogeneity of AD may reflect differences in the expression
levels of cancer-related pathways. We have utilized sets of genes
representing 27 separate cellular processes (referred to as
pathways) to investigate relationships between tumors and
separate AD subtypes. The relationships observed between
gene expression, clinical information including survival, and AD
pathology we suggest, have potential translational and clinical
implications. Our overall study design is summarized in Figure 1
and was independently validated in two additional independent
datasets.
Methods
Gene Expression Data
Affymetrix 133A data was obtained for the 443 lung AD
described by Shedden et al [3] with the entire set of arrays quantile
normalized forthatstudy.A subsetof11tumorswereremoved from
further analysis based on neuroendocrine features following
pathological review of all tumors by one of the study pathologists
(W. Travis). The expression of CHGA, SCG2, CHGB (chromo-
granin), NCAM1 (CD56) and SYP (synaptophysin) in the micro-
array data were used to support this decision as they are highly
expressed in large cell neuroendocrine carcinomas (LCNEC).
Statistical Methods
Prior to any data analysis, individual tumor gene expression
levels were log2-transformed to remove skewness and mean-
centered within each of the four sites [3] to remove potential site
effects not removed by the quantile normalization. The four sets of
tumor data were combined and the dataset reduced by removing
approximately 25% of the least-varying genes across all samples.
The final dataset for analysis included 432 tumors with 16,660 (of
the original 22,214) genes. All final regression models were chosen
using stepwise model selection, based on Akaike’s Information
Criterion (AIC, lower means better fit). All source code is included
in the Supplemental Data as R Code S1.
Clustering
Tumors were hierarchically clustered based on all 16,660 genes
in the final data set using Cluster and Treeview Eisen software [8].
Genes and arrays were median-centered within the Cluster
program, with the average linkage method of clustering used.
‘‘Clusters’’ were identified using the zero correlation level as a
separator of distinct groups, such that the level of correlation
between clusters is negative but the nodes within a single cluster
have positive correlation. Pearson correlations between each gene
and an indicator variable for each cluster were computed to find
those genes with significantly higher or lower expression within
one group as compared to all other tumors, and the Bonferonni
method was used to conservatively adjust the p-values for multiple
comparisons. This analysis resulted in two lists of genes for each
cluster, those over-expressed and those under-expressed within the
cluster (as compared to the other clusters). Descriptive statistics by
cluster were produced for each of the clinical variables (see
Table 1). Gene enrichment analysis was used to test the gene sets
for enrichment of the pathways described previously (see Table 2),
using Fisher’s Exact Tests to determine the pathways described in
each list. Kaplan-Meier survival curves were plotted for each
cluster and the associated log-rank test was computed to determine
differences in outcome by cluster.
Pathways
Pathway gene lists were developed based on primary literature
sources, KEGG pathways and by referencing OMIM (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM). The pathways
include only genes that are highly specific to the pathway and act
to either stimulate or suppress the pathway (as indicated). The
embryonic stem cell pathway (ESC) was based on genes
Figure 1. Overall Study Design. We developed cellular pathway expression summaries and tested the relationship of each to pathological
subtypes of lung adenocarcinoma (AD). We also tested each pathway’s association with survival. Because the cellular pathways are driving the
pathological differences, the relationship between pathology and prognosis is secondary to the relationship between the cellular pathway and
prognosis (indicated by a thinner line with both component colors). We also directly tested the relationship between pathology and prognosis to
examine the need for molecular information.
doi:10.1371/journal.pone.0011712.g001
Survival Pathways
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pathway lists and references are provided in the Supplemental
Data as Gene Lists S1 and References S1. Pathway expression
data were formed as the arithmetic mean of all genes in the final
dataset within the compiled lists, leaving one value for each
tumor for each pathway.
Cluster Membership
Prior to performing any further analyses, pathways that were
highly predicted by other pathway(s) were removed from the
analyses to protect against multicolinearity (redundancy among
predictive variables). Each pathway was used as the outcome
variable in a linear regression with all other pathways as
predictors, and the pathway with the highest R
2 was removed.
This process was continued until no pathway was predicted with
an R
2 at least equal to 0.7. In order to determine general gene-
based tumor profiles using pathways of interest and the clinical
data at hand, logistic regression was used with cluster member-
ship as the outcome. The pathways were used as covariates along
with age, gender, stage, and tumor grade.
Survival Analyses
A Cox proportional-hazards model was fit to assess differences
in 5-year survival using the same covariates as described above.
The proportional-hazards assumption was tested for the final
model to examine the model’s appropriateness. Additionally, a
Cox proportional hazards model was fit to the AD subtypes.
Kaplan-Meier curves and associated log-rank tests were computed
for selected descriptive statistics as well as to compare over- and
under-expression (from the mean) of selected pathways.
Table 2. Select Gene Enrichment p-values.
Pathway Cluster 1 (+) Cluster 2 (+) Cluster 3 (+) Cluster 1 (2) Cluster 2 (2) Cluster 3 (2)
Complement 0.015 NS NS NS NS ,0.0001
Chemokine NS ,0.0001 NS ,0.0001 NS NS
T-cell NS ,0.0001 NS 0.0019 NS NS
Antigen NS 0.00086 NS NS NS 0.028
NFKB NS 0.0015 NS NS NS NS
B-cell NS 0.0087 NS NS NS NS
ESC NS NS ,0.0001 ,0.0001 NS NS
Cell Cycle (+)N S N S ,0.0001 ,0.0001 NS NS
The complement pathway had a significant number of probe sets that were also in the Cluster 1 positively (over-expressed) correlated (p,0.05 after Bonferroni
correction for multiple tests) probe set list. The complement pathway also had a significant number of probe sets that were also in the Cluster 3 negatively correlated
probe set list. The chemokine, T-cell, antigen, NF-kB and B-cell pathways were significantly enriched in the positively correlated Cluster 2 probe set list. The chemokine
and T-cell pathways were also significantly enriched in the Cluster 1 negatively correlated probe set list and the antigen pathway was significantly enriched in the
Cluster 3 negatively correlated probe set list. The embryonic stem cell (ESC) and cell cycle stimulatory (CC+) pathways were significantly enriched in the Cluster 3
positively correlated probe set list as well as the Cluster 1 negatively correlated probe set list.
doi:10.1371/journal.pone.0011712.t002
Table 1. Cluster Descriptives.
Variable Overall (%) Cluster 1 (%) Cluster 2 (%) Cluster 3 (%) p-value
Number of Tumors 432 (100) 137 (32) 130 (30) 165 (38) N/A
Stage 1 268 (62) 97 (36) 85 (32) 89 (33) 0.0098
Stage 2 93 (22) 23 (25) 25 (27) 45 (48) 0.064
Stage 3 69 (16) 16 (23) 23 (33) 30 (43) 0.26
Unknown Stage 2101N / A
High Grade 160 (37) 13 (8) 47 (29) 100 (63) ,0.0001
Low/Intermediate Grade 265 (61) 123 (46) 82 (31) 60 (23) ,0.0001
Unknown Grade 7 (2) 1 1 5 N/A
Male 217 (50) 70 (32) 62 (29) 88 (41) 0.59
Female 215 (50) 67 (31) 68 (32) 77 (36) 0.59
Age at Diagnosis 64.5 66.6 63.1 63.8 0.0095
Percent CIS (Mean) 6.5 12.2 5.4 1.8 ,0.0001
Percent Papillary (Mean) 30.7 45.3 27.3 19.3 ,0.0001
Percent Acinar (Mean) 34.3 32.4 39.7 31.4 0.042
Percent Solid (Mean) 25.9 9.0 25.9 42.4 ,0.0001
Chi-squared tests showed significant differences between the clusters for the presence of stage 1 and stage 2 tumors as well as grade. There were no significant
differences for stage 3 and sex between the clusters. Abbreviations: CIS, carcinoma in situ.
doi:10.1371/journal.pone.0011712.t001
Survival Pathways
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T h ep e r c e n t a g eo fe a c hA Ds u b t y p ep r e s e n ti nt h ep r i m a r y
tumor in 5% increments (as determined by W. Travis) was
recorded for each tumor. Linear regression models were fit to
the estimated percentage using the final set of pathways as
covariates. Pathological review in 5% increments was not
available for one AD cohort from [3], leaving the sample size of
n=323 for the analyses involving subtype. Logistic regression
was used to model the odds of the presence of each particular
subtype (separate model for each subtype) with the same
covariates.
Validation
Two independent cohorts of lung AD with gene expression data
and new complete and comparable pathological review were used
to assess the findings with one cohort from Nagoya, Japan
(Takahashi et al [10]) containing 87 lung AD, and another 89 lung
AD from Grenoble, France (Brambilla et al [11]). The same
statistical and pathological analyses were performed separately on
each of these groups of tumors for a qualitative validation of the
results from the 432 AD analyzed in this study. Statisticians from
each of these groups followed the methods described above as
closely as possible.
Results
Overall
As graphically described in Figure 1, we developed cellular
pathway expression summaries then tested each pathway to
determine its relationship to pathologic subtypes of lung
adenocarcinoma (AD). We also tested each pathway’s association
with survival. We hypothesize that the cellular pathways are likely
driving the pathologic differences, therefore the relationship
between pathology and prognosis is secondary to the relationship
between the cellular pathway and prognosis. However, we also
directly tested the relationship between pathology and prognosis to
examine the need for molecular information.
Clustering
Hierarchical clustering of all 432 samples with the 16,660 most
variably expressed genes yielded three distinct lung AD groups. A
dendrogram of the three clusters including a heat-map of the 200
most significantly over-expressed genes in each cluster is shown in
Figure 2. The patients within each cluster demonstrated a
significant (p-value ,0.001) difference in overall survival
(Figure 3). Cluster 3 includes patients with worse overall survival
Figure 3. Clusters show survival differences. Kaplan-Meier survival
curves for 432 lung adenocarcinomas (AD) showing a significant
difference between clusters (log-rank test: p=0.000194). Abbreviations:
Cluster 1, left most cluster in Figure 2; Cluster 2, middle cluster is
Figure 2; Cluster 3, right most cluster in Figure 2.
doi:10.1371/journal.pone.0011712.g003
Figure 2. Hierarchical clustering yields three distinct groups. Hierarchical clustering of all 432 lung adenocarcinomas (AD) which shows three
main groups of tumors denoted by yellow, blue and orange in the dendrogram. Below is a heat map that represents the 200 genes that are most
highly correlated to the left most cluster followed by the middle cluster and the right most cluster. Red indicates relative over-expression (compared
to the median) while green indicates relative under-expression.
doi:10.1371/journal.pone.0011712.g002
Survival Pathways
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more well-differentiated and had a more favorable outcome.
Complete clinical and pathological descriptive statistics for each
cluster are provided in Table 1.
Following selected gene enrichment and determination of the
genes most associated with each cluster, the correlation of each
cluster to the 27 separate pathways was assessed. Those pathways
significantly associated with cluster membership are shown in
Table 2. More detailed results are provided in Supplemental Data
as Table S10. Cluster 3 demonstrating the poorest survival
outcome showed significant enrichment of the embryonic stem cell
(ESC) and cell cycle stimulatory (CC+) pathways. The high cell
cycle expression is consistent with the poorer outcome and more
aggressive AD in this group. Cluster 2 showed significant
enrichment of several immune-related pathways (complement,
T-cell, B-cell, antigen, NF-kB) potentially reflecting either
increased immune cell presence, or their activity in these tumors.
These tumors may be mounting a more successful immune
response, given their improved outcome relative to Cluster 3.
Cluster 1 also showed enrichment for several immune response
pathways but most interestingly showed strong enrichment for the
under-expression of the CC+ and ESC pathways indicating that
cell proliferation is lowest in tumors within this cluster.
Cluster Membership
Modeling the odds of cluster membership (performed separately
for each cluster), the findings are consistent with the pathway
enrichment results. The final logistic regression models are shown
Table 3. Clusters and Pathways.
Cluster 1 Cluster 2 Cluster 3
Pathway Name Coefficient P-value Coefficient P-value Coefficient P-value
Intercept 22.95 0.0020 0.34 0.71 20.74 0.0010
Cell Cycle (+) 20.76 ,0.0001 20.70 ,0.0001 1.69 ,0.0001
ESC NA NA NA NA NA NA
B-cell 20.57 0.0023 0.52 0.0049 NA NA
T-cell NA NA NA NA NA NA
Antigen NA NA 0.87 0.0007 20.47 0.013
AKT/PI3K NA NA NA NA 20.61 0.0014
IGF-1 -0.88 ,0.0001 0.99 ,0.0001 NA NA
Chemokine NA NA NA NA NA NA
NF-kB NA NA NA NA NA NA
Notch NA NA 0.34 0.048 NA NA
JAK/STAT NA NA 0.48 0.016 NA NA
Complement 0.56 0.0023 NA NA 20.81 ,0.0001
mTOR NA NA NA NA NA NA
Cell Cycle (2) NA NA NA NA NA NA
Angiogenesis 20.47 0.011 NA NA 0.39 0.035
IL-stimulatory NA NA 20.28 0.11 0.40 0.029
IL-suppressive 20.37 0.030 NA NA NA NA
Interferon 0.36 0.010 20.27 0.056 0.30 0.073
EGFR NA NA 20.26 0.11 NA NA
PDGF NA NA 0.56 0.0007 20.41 0.016
Hypoxia 0.35 0.033 NA NA 20.39 0.029
PTEN NA NA NA NA NA NA
Pro-apoptosis NA NA NA NA NA NA
Anti-apoptosis 0.40 0.041 20.46 0.030 NA NA
TGF-b NA NA NA NA 20.36 0.045
Hedgehog NA NA NA NA NA NA
Wnt 0.38 0.022 NA NA 20.43 0.015
Male NA NA NA NA 20.44 0.16
Age 0.032 0.023 20.030 0.026 NA NA
Grade 21.49 ,0.0001 0.50 0.13 NA NA
Stage NA NA NA NA NA NA
Tumors with lower levels of the cell cycle stimulatory (CC+) were more likely to be in Cluster 1 or 2, other pathways held constant. Tumors with higher levels of the IGF-1
pathway were more likely to be in Cluster 2 and less likely to be in Cluster 1. Samples with increased antigen pathway expression were more likely to be in Cluster 2 and
less likely to be in Cluster 3. Tumors with increased complement pathway expression were more likely to be in Cluster 1 and less likely to be in Cluster 3. NA indicates
that the variable was excluded during model selection and thus deemed unimportant.
doi:10.1371/journal.pone.0011712.t003
Survival Pathways
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were far more likely to be in Cluster 3 than in the other two
clusters. Tumors with greater complement pathway values were
more likely to be in Cluster 2 than Cluster 1 or Cluster 3.
Increased immune response pathways corresponded largely to a
greater likelihood of tumor membership in Cluster 2.
Survival Analyses
The multivariate Cox proportional-hazards model confirmed
results from previous studies that stage and age are strong
prognostic indicators in AD (final model shown in Table 4 and
Kaplan-Meier survival curves shown in Figure 4). However,
several pathways gave additional prognostic information across all
stages of tumors and some had significant interactions with stage.
Increased expression of the CC+ pathway yielded a significantly
increased hazard rate while increased expression of EGFR and B-
cell pathways was associated with a decreased hazard rate, holding
other covariates constant. Higher values of the Notch and the
immunosuppressive interleukin (IL-) pathways were associated
with poorer outcomes in stage 3 and stage 2 patients respectively.
Kaplan-Meier survival curves based on either the over- or under-
expression (relative to the mean of all tumors) of the CC+ pathway
are shown in Figure 5. Additional information is given in the
Supplemental Data as Table S15.
Subtype Associations
Final reduced models showing pathways correlated with the
percent of each subtype are shown in Table 5. Results for each AD
subtype using presence of subtype can be found in Supplemental
Data as Table S11, Table S12, Table S13 and Table S14. Tumors
with higher expression of the CC+ pathway, holding other
covariates constant, tended to contain less of the carcinoma in situ
(CIS) component. Greater values of the complement and PGDF
pathways, as well as lower values of the EGFR pathway, were
associated with a greater acinar component after adjusting for
other covariates. Tumors with lower levels of CC+ pathway
expression and higher levels of Hedgehog, Notch, and the EGFR
pathway expression tended to have more of a papillary
component. Finally, tumors with greater CC+, anti-apoptosis
and angiogenic pathways as well as lower Notch and complement
pathways tended to have a greater proportion of the solid
component.
Subtype Survival Analyses
Because the pathological subtypes are so highly associated with
certain pathways they dropped out of the multivariate survival
analysis described in Table 4 (see Methods) during model
selection. Therefore we found that information on the pathological
subtype gives little additional prognostic value, when using either
the subtype presence indicator or the continuous variable.
However, a multivariate Cox model including only the patholog-
ical subtypes suggested that patients with some solid component
had almost twice the hazard as those with no solid component,
with an associated p-value of 0.002 as shown in Table 6. We also
observed that the presence of a solid component was associated
with a poorer survival in all patients and within either stage 1 or
stage 3 patients (Figure 6 A–C). The presence of BAC component
was favorable for survival as was presence of a Papillary
component in stage 3 patients of this cohort (Figure 6 D–F).
Using the percent subtype variable, we found no significant
survival differences as shown in Supplemental Data as Table S16.
Validation
In the Japanese cohort of 87 AD and in the French cohort of 89
AD, hierarchical clustering using the same parameters as
described for the current analysis also produced three clusters. A
significant difference was also found between survival rates of the
different clusters via a log-rank test (p,0.001) in the Japanese
cohort. Cluster 1 had significantly better survival than the other
two clusters, with hazard ratios of greater than five in both cases
(Cox-PH p-values ,0.002 for each). Similarly, in the French
cohort three clusters were found with a significant difference
between survival rates (p,0.001). Using the same methods as
mentioned above, pathway expression was summarized using the
mean, and models were fit using these pathways as predictors. For
both validation sites, logistic regression models on cluster
membership could not be fit apparently due to an insufficient
amount of data in these smaller cohorts. Gene enrichment on each
set of data however, showed significant enrichment of the cell cycle
stimulatory pathway and embryonic stem cell (ESC) pathway in
one cluster (p,0.001 in each set of data). Differences between
clusters were also seen in apoptosis (stimulatory and suppressive)
and immune response (such as antigen) pathways in each set of
data. Additional gene enrichment results can be seen in the
Supplemental Data as Table S10.
In the pathway survival model using the Japanese cohort, the
cell cycle stimulatory pathway (CC+) was found to be significantly
related to poorer outcome (hazard ratio 1.61, p=0.02) and the B-
cell pathway marginally related to better outcome (hazard ratio
Table 4. Survival and Pathways.
Pathway Name
or Other Variable Coefficient P-value
Stage 2 1.00 ,0.0001
Stage 3 1.56 ,0.0001
Cell Cycle (+) 0.37 ,0.0001
Notch 0.015 0.91
Hedgehog 0.14 0.09
B-cell 20.26 0.037
Hypoxia 20.20 0.11
EGFR 20.21 0.014
IL-suppressive 0.19 0.20
Cell Cycle (2) 20.14 0.12
Age 0.035 ,0.0001
Stage 2 : Notch 20.056 0.78
Stage 3 : Notch 0.39 0.043
Stage 2 : B-cell 20.39 0.11
Stage 3 : B-cell 0.21 0.36
Stage 2 : Hypoxia 0.26 0.17
Stage 3 : Hypoxia 0.42 0.063
Stage 2 : IL-suppressive 0.70 0.0045
Stage 3 : IL-suppressive 0.11 0.61
The cell cycle stimulatory (CC+) pathway gives additional prognostic
information beyond standard clinical covariates such as stage and age, where
patients with greater expression levels of the CC+ pathway have an increased
hazard compared to those with relative underexpression. The B-cell and EGFR
pathways also give additional information where patients with relative
overexpression of either of these pathways to better although the relationship
with the B-cell pathway only exists in stage 1 patients. In addition, stage 3
patients with relative overexpression of the Notch or the response to hypoxia
pathway do worse while stage 2 patients with relative overexpression of
pathway representing activity of immunosuppressive interleukins did poorer.
Variables not listed were dropped during model selection.
doi:10.1371/journal.pone.0011712.t004
Survival Pathways
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Interactions were again not fit due to the smaller amount of data.
In the French cohort, which consisted of mostly stage 1 cancers,
the IL-suppressive pathway was found to be significantly related to
poorer outcome (hazard ratio 3.78, p,0.001), the mTOR
pathway was found to be significantly related to poorer outcome
(hazard ratio 2.41, p=0.004), and the antigen pathway was found
to be significantly related to better survival (hazard ratio 0.19,
p=0.002) after adjusting for the other pathways in the final model.
Once again, interactions were not included in the model due to the
smaller sample size.
Gaussian regression models were fit to the percent of each AD
subtype, as determined by pathological review for both the Japanese
and French AD cohorts. As in our analyses, in the Japanese cohort
AD with higher cell cycle stimulatory pathway expression tend to be
more of the solid subtype (p,0.001) and less of the papillary and CIS
Figure 4. Stage, grade, sex and pathology effects on survival. Log-rank tests of differences between Kaplan Meier survival curves verify that
the dataset is consistent with previous results. Higher stage patients do significantly poorer as compared to lower stages (A) and high grade patients
(B) (poor differentiation) have increased hazards compared to low or intermediate grade patients. Gender is a marginally significant prognostic
indicator; males have poorer survival (C). Additionally we examined pathology (D) defined by major lung adenocarcinoma (AD) subtype (plurality of
tumor cross section). There was no significant overall difference between the four main subtypes as well as tumors that did not fall into one of these
categories. Abbreviations: CIS, carcinoma in situ.
doi:10.1371/journal.pone.0011712.g004
Survival Pathways
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pathways. Also, tumors higher in Wnt expression tended to contain
less of the solid subtype (p,0.01), other pathways held constant. In
the French cohort, AD with higher cell cycle stimulatory pathway
expression tended to be marginally more acinar (p=0.08), tumors
with higher mTOR pathway expression were significantly more of
the solid subtype (p=0.009), and tumors with higher IL-stimulatory
pathway expression had significantly less CIS and papillary
components (p=0.002 and p,0.0001 respectively), with significantly
more acinar and solid components (p=0.01 and p,0.0001
respectively). We provide qualitative assessments of both the
pathological and pathway correspondence between the three datasets
in Table 7. Also see validation results: Figure S1, Figure S2, Figure
S3, Figure S4, Figure S5, Table S1, Table S2, Table S3, Table S4,
Table S5, Table S6, Table S7, Table S8 and Table S9.
Discussion
Lung adenocarcinomas (AD) are highly heterogeneous demon-
strating a large number of genetic alterations [4,5] and several
well-recognized pathological subtypes [6]. A better understanding
of this heterogeneity and potential clinical-pathological relation-
Figure 5. Stage specific survival differences of cell cycle pathway. (A) Kaplan-Meier survival analysis of the cell cycle stimulatory (CC+)
pathway shows that patients with relative over-expression of CC+ do significantly worse (p=0.000113). This trend is consistent inside each stage
however is only marginally significant (p=0.062) in stage 1 patients (B), not significant in stage 2 patients (C) and highly significant (p=0.0042) in
stage 3 patients (D). Abbreviations: w/, with; w/o, without.
doi:10.1371/journal.pone.0011712.g005
Survival Pathways
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treating patient subgroups. Although prior analyses of AD using
gene expression have often revealed three subgroups [12,13] no
studies have integrated clinical covariates, pathological subtype
[3–5,7] and gene expression-based pathway analyses. Based on
unsupervised analysis using 16,660 genes and the large AD dataset
of 432 tumors, we observed three separate clusters of tumors. We
found a significant difference in survival between clusters of
tumors suggesting that tumors are meaningfully classified by their
common features of gene expression while ‘‘major pathological
subtype’’ categorization alone does not. Gene enrichment showed
that of the selected pathways we examined, cell proliferation and
immune response pathways were most responsible for the
separation of the three clusters (see Table 2). Further analyses of
additional pathways indicate that the tumors that comprise these
separate groups largely share pathway expression profiles (see
Table 3). Beyond the survival differences between clusters, a Cox
proportional-hazards model also gave prognostic profiles based on
the pathways that were, in addition to that given by stage and age,
Table 5. Pathology and Pathways.
CIS-ness (%) Acinar-ness (%) Papillary-ness (%) Solid-ness (%)
Pathway Name Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value
Intercept 6.32 ,0.0001 34.72 ,0.0001 30.34 ,0.0001 26.92 ,0.0001
Cell Cycle (+) 25.65 ,0.0001 4.38 0.031 28.89 ,0.0001 7.41 0.0011
ESC NA NA NA NA NA NA NA NA
B-cell NA NA 24.04 0.034 NA NA 3.53 0.080
T-cell NA NA NA NA NA NA NA NA
Antigen NA NA NA NA NA NA NA NA
AKT/PI3K 1.58 0.072 NA NA NA NA NA NA
IGF-1 NA NA 6.81 0.0001 23.95 0.028 NA NA
Chemokine NA NA NA NA NA NA NA NA
NF-kB NA NA NA NA NA NA NA NA
Notch NA NA NA NA 5.28 0.0068 26.85 0.0007
JAK/STAT NA NA NA NA NA NA 3.081 0.14
Complement NA NA 5.61 0.0014 NA NA 26.53 0.0015
mTOR NA NA 24.99 0.015 NA NA 3.65 0.087
Cell Cycle (2) NA NA 2.7 0.077 NA NA NA NA
Angiogenesis NA NA 23.39 0.042 25.34 0.0052 8.21 ,0.0001
IL-stimulatory 22.32 0.012 NA NA NA NA NA NA
IL-suppressive NA NA NA NA NA NA NA NA
Interferon NA NA NA NA NA NA NA NA
EGFR NA NA 24.29 0.0035 5.58 0.0003 NA NA
PDGF NA NA 3.68 0.025 NA NA NA NA
Hypoxia NA NA NA NA NA NA NA NA
PTEN NA NA NA NA NA NA NA NA
Pro-apoptosis NA NA NA NA NA NA 23.71 0.16
Anti-apoptosis 1.71 0.079 23.40 0.075 23.68 0.056 6.21 0.0079
TGF-b NA NA NA NA NA NA NA NA
Hedgehog NA NA NA NA 3.77 0.028 24.45 0.010
Wnt NA NA 2.36 0.13 23.10 0.087 24.10 0.025
Carcinoma in situ (CIS) tumors are best described by relative underexpression of the cell cycle stimulatory (CC+) pathway. This relationship was consistent when taking
into account only the presence or absence (+/2) of a CIS component of the tumor as well as the percentage (%) of the tumor that was CIS. Acinar tumors tended to
have relative overexpression of the complement and PDGF pathways and relative underexpression of the angiogenesis pathway. Relative underexpression of the CC+
pathway was a strong indicator of papillary tumors as were relative overexpression of the EGFR and hedgehog pathways. Solid tumors were best defined by relative
overexpression of the CC+, JAK/STAT and angiogenesis pathways and by relative underexpression of the Notch pathway. NA means the variable was excluded during
model selection.
doi:10.1371/journal.pone.0011712.t005
Table 6. Pathology and Survival.
Pathological Subtype Coefficient P-value
Acinar-ness .0 0.88 0.66
Solid-ness .0 1.92 0.0020
Papillary-ness .0 0.89 0.57
CIS-ness .0 0.85 0.45
Using a multivariate analysis we found that the presence of any solid
component lead to twice the hazard as compared to tumors without a solid
component.
doi:10.1371/journal.pone.0011712.t006
Survival Pathways
PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11712indicating the existence of further subgroups not captured by the
hierarchical clustering.
We found relationships between pathways and the pathological-
based subtypes of the AD tumors (see Table 5). This suggests that
there are differences between AD subtypes in the activation and
expression of cancer-related pathways. Among the most intriguing
is the EGFR-papillary AD subtype connection, previously
proposed [6]. Moreover, papillary tumors, which are character-
ized by papillae, tend to overexpress the hedgehog pathway.
Hedgehog signaling is known to lead to the bifurcation of
structures during development, which may influence this mor-
phology [14]. In addition, solid tumors are best characterized by
the highly-significant, over-expression of the cell cycle stimulatory
(CC+) pathway and that tumors with any solid component had
significantly higher hazard as compared to those without a solid
component. They do not, however, show a strong relationship to a
specific pathway indicating perhaps that there is a great deal of
variability in which pathway is driving the cellular proliferation,
yet the common feature is the increase in cell proliferation.
Independent qualitative validation on two AD cohorts showed a
group of tumors in each set with higher expression of cell
proliferation genes than the other tumors. In the Japanese AD
cohort, tumors with the cell cycle positive (CC+) pathway were
associated with poorer outcome after adjusting for other pathways
and for clinical variables such as stage. In the French cohort
containing mostly stage 1 AD, this pathway was not significantly
prognostic however we did not see a significant interaction with
stage in our data so this could be due to the smaller sample in that
validation set. Immune response pathways such as B-cell,
complement, and antigen were found to be predictive of better
survival in all three sets of AD tumors. Overall, it appears that cell
proliferation and immune response combine to form a common
predictor of survival, although it also appears that there is
heterogeneity in which pathways make up a particular tumor’s
profile.
In addition to the survival validation observed in our analyses,
we also saw common characteristics among AD subtypes, such as
increased cell proliferation pathway expression and a greater solid
component also detected in the Japanese cohort analyses. Further,
the EGFR-papillary connection was also detected in the French
AD cohort at a similar magnitude as it was found in the North
American ADs, although interestingly this was not the case in the
Japanese AD cohort. It is known that EGFR mutations are much
more frequent in the Asian population of lung AD and this may
influence the association with a given subtype however this result is
interesting and worthy of additional investigation. The validation
analyses also showed the heterogeneity of tumors across data sets
and possibly across regions of the World. For example, in our set
Figure 6. Survival differences for different pathologies. (A) Kaplan-Meier survival analysis of solid lung adenocarcinoma (AD) shows that
patients with any solid component do significant worse (p=0.000166) than those with no solid component. This trend is highly significant
(p=0.00562) in stage 1 patients (B) and marginally significant (p=0.0295) in stage 3 patients (C). Those patients with any carcinoma in situ (CIS)
component (D) did significantly better (p=0.0342) than those without any CIS component. Comparing patients with papillary component (E)t o
those without any papillary component showed no significant difference but in stage 3 patients (F) those with some papillary component did
significantly better than those without any papillary component. Abbreviations: w/, with; w/o, without.
doi:10.1371/journal.pone.0011712.g006
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predictor of survival (due to a high correlation with pathways that
were not selected out of the model), but in both validation sets
higher expression of the mTOR pathway was associated with
poorer outcome which is consistent with previous reports [15].
Also, increased cell proliferation and a larger solid component was
highly significant in both the North American and the Japanese
lung cohorts, although not in the mostly stage 1 French cohort.
These relationships provide an interesting opportunity to
examine interactions between tumor pathology and active
pathway affecting the progression of the relatively good outcome
CIS lesions to those with more poor outcome and often solid
morphology. Two of the three datasets showed reduced cell cycle
activity and an increase in the interleukin stimulatory pathway
(IL+) with elevated CIS component. However, in two of three
datasets (as mentioned above) there was an association between
increased EGFR and reduced cell cycle activity and the
percentage of papillary component. This potentially indicates that
papillary tumors progress from CIS tumors resulting from an
increase in EGFR pathway expression. Similarly, progression from
CIS to acinar may be driven by increased PDGF and decreased
angiogenic pathway activity. Solid component tumors showed an
association with increased CC+ and decreased complement
pathways in two of the three datasets while all three datasets
showed an association between solid component and decreased
Wnt signaling. Clearly, additional studies are needed to further
validate these findings yet they represent interesting data in light of
the vast heterogeneity of AD.
It is important to note that our analyses are an attempt to
describe meaningful differences between AD, rather than an
attempt to assess each individual pathway’s importance. For
example, we identified the set of pathways that best predicts
survival instead of the univariate survival significance of each
pathway. This would not imply that a pathway not found to be a
significant predictor of survival in our multivariate analyses lacks
clinical significance, just that the survival differences were better
explained by a set of other pathways. In general however, across
AD and representing different regions of the world, many aspects
Table 7. Overall Qualitative Summary.
Survival Relationship Pathology Relationship
Pathway Michigan France Japan Michigan France Japan
Cell Cycle (+) X (poor) X (poor) CIS (2); Acinar (+);
Pap (2); Solid (+)
CIS (2); Pap (2); Solid (+)
ESC
B-cell X (good) Acinar (2)
T-cell
Antigen X(good)
AKT/PI3K X (poor) X (poor) Pap (2) Acinar (+); Solid (2)
IGF-1 X (good) Acinar (+); Pap (2) Acinar (+); Pap (+)
Chemokine
NF-kB
Notch X (poor) Pap (+); Solid (2) Acinar (+)
JAK/STAT X (poor)
Complement X (good) Acinar (+); Solid (2) Pap (+); Solid (2)
mTOR X (poor) X (poor) Acinar (2) Solid (+)
Cell Cycle (2) X (good) Acinar (2) Acinar (+); Pap (2)
Angiogenesis X (poor) Acinar (2); Pap (2); Solid (+) CIS (+); Acinar (2) CIS (2)
IL-stimulatory X (poor) CIS (2) CIS (2); Acinar (+);
Pap (+); Solid (2)
Acinar (2)
IL-suppressive X (poor)
Interferon X (good) Pap (+)
EGFR X (good) Acinar (2); Pap (+) Pap (+)
PDGF X (poor) Acinar (+) Acinar (+) CIS (+); Pap (2); Solid (+)
Hypoxia X (poor) Pap (+) Acinar (+)
PTEN
Pro-apoptosis X (good) CIS (2)
Anti-apoptosis Solid (+)
TGF-b Pap (2); Solid (+)
Hedgehog X (poor) Pap (+); Solid (2)
Wnt Solid (2) Acinar (+); Solid (2) Solid (2)
An overall qualitative summary. Items in italics indicate validation in two or three of the three datasets. Abbreviations: poor, statistically poor survival; good, statistically
good survival; CIS, carcinoma in situ; Pap, papillary; (+), statistically significant positive association between pathway and given subtype; (2), statistically significant
negative association between pathway and given subtype.
doi:10.1371/journal.pone.0011712.t007
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uniform classification will allow potential new therapeutic
strategies to be developed for lung adenocarcinomas.
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